JP2024542523A5 - - Google Patents
Info
- Publication number
- JP2024542523A5 JP2024542523A5 JP2024530556A JP2024530556A JP2024542523A5 JP 2024542523 A5 JP2024542523 A5 JP 2024542523A5 JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024542523 A5 JP2024542523 A5 JP 2024542523A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- approximately
- gene
- disease
- neurodegenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282615P | 2021-11-23 | 2021-11-23 | |
| US63/282,615 | 2021-11-23 | ||
| US202263393573P | 2022-07-29 | 2022-07-29 | |
| US63/393,573 | 2022-07-29 | ||
| PCT/US2022/050940 WO2023097029A1 (en) | 2021-11-23 | 2022-11-23 | Therapy selection and treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542523A JP2024542523A (ja) | 2024-11-15 |
| JP2024542523A5 true JP2024542523A5 (https=) | 2025-12-03 |
Family
ID=86540341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024530556A Pending JP2024542523A (ja) | 2021-11-23 | 2022-11-23 | 神経変性障害の治療選択及び治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240417798A1 (https=) |
| EP (1) | EP4436573A4 (https=) |
| JP (1) | JP2024542523A (https=) |
| AU (1) | AU2022396274A1 (https=) |
| CA (1) | CA3237579A1 (https=) |
| WO (1) | WO2023097029A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054599A1 (en) * | 2023-09-08 | 2025-03-13 | Anavex Life Sciences Corp. | Treatment and prevention of cerebral atrophy |
| WO2025117826A1 (en) * | 2023-11-30 | 2025-06-05 | Anavex Life Sciences Corp. | Methods of using surrogate biomarkers in sigma-1 receptor therapy |
| CN117679516A (zh) * | 2023-12-13 | 2024-03-12 | 广东工业大学 | Ndufa7基因在制备改善和/或治疗线粒体功能障碍相关疾病的药物中的应用 |
| WO2025231180A1 (en) * | 2024-05-01 | 2025-11-06 | Anavex Life Sciences Corp. | Blarcamesine correction of eeg biomarkers in fragile x syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7476103B1 (en) * | 2005-10-17 | 2009-01-13 | Penelope Anne Norman | Science party kit and method |
| CN106501251A (zh) * | 2016-12-09 | 2017-03-15 | 防城港市质量技术监督局 | 一种用于检测大麻油的试剂盒 |
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| AU2019269739B2 (en) * | 2018-05-18 | 2025-12-18 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| US12352767B2 (en) * | 2018-07-16 | 2025-07-08 | University Of Virginia Patent Foundation | Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity |
-
2022
- 2022-11-23 WO PCT/US2022/050940 patent/WO2023097029A1/en not_active Ceased
- 2022-11-23 US US18/712,387 patent/US20240417798A1/en active Pending
- 2022-11-23 AU AU2022396274A patent/AU2022396274A1/en active Pending
- 2022-11-23 EP EP22899408.3A patent/EP4436573A4/en active Pending
- 2022-11-23 JP JP2024530556A patent/JP2024542523A/ja active Pending
- 2022-11-23 CA CA3237579A patent/CA3237579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542523A5 (https=) | ||
| Reif et al. | Precision medicine in genetic epilepsies: break of dawn? | |
| Van Hilten et al. | Multifocal or generalized tonic dystonia of complex regional pain syndrome: a distinct clinical entity associated with HLA‐DR13 | |
| Plecko et al. | Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine‐dependent epilepsy | |
| JP2002507564A (ja) | βアミロイドタンパク質を減少させるための方法 | |
| Meda et al. | Genetic interactions associated with 12-month atrophy in hippocampus and entorhinal cortex in Alzheimer's Disease Neuroimaging Initiative | |
| JP7347743B2 (ja) | トラジピタントによるアトピー性皮膚炎の改善された治療 | |
| Ebner et al. | Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference | |
| TW202308635A (zh) | 治療與監測帕金森氏病之方法 | |
| Bame et al. | Amino Acids as biomarkers in the SOD1G93A mouse model of ALS | |
| JP5713887B2 (ja) | 筋変性疾患の検出方法、及び治療効果判定方法 | |
| WO2024074133A1 (en) | Protein marker for assessing and treating neurodegenerative diseases | |
| Quigg et al. | Dual epileptic foci in a single patient express distinct temporal patterns dependent on limbic versus nonlimbic brain location | |
| US20170248586A1 (en) | Marker For Depression, Assay Method, Method For Determining Depression, Screening Method For Antidepressants, And Kit | |
| Liu et al. | circ0066187 promotes pulmonary fibrogenesis through targeting STAT3-mediated metabolism signal pathway | |
| CN103547289A (zh) | 治疗阿尔茨海默氏病的方法和组合物 | |
| CN119856057A (zh) | 用于监测共济蛋白替代疗法的共济蛋白敏感性脂质标志物 | |
| Asai et al. | Status epilepticus decreases brain cytochrome P450 2D4 expression in rats | |
| Reynolds | The neurochemistry of schizophrenia | |
| US20130196980A1 (en) | Diagnostic agent, diagnostic method and therapeutic agent for fibromyalgia | |
| US11406613B2 (en) | Treatment of osteoarthritis | |
| Yanping et al. | Yinxie I Formula attenuates imiquimod-induced psoriasis-like skin inflammation via IL-23/IL-17 axis | |
| JP2020153742A (ja) | 進行期非扁平上皮肺癌患者の化学療法反応性を評価するための情報を提供する方法 | |
| CN117615768A (zh) | 用于帕金森病的nad增效疗法 | |
| Chen et al. | Pterostilbene targets microglia-mediated neuroinflammation for Alzheimer therapy |